Jay T. Backstrom

CIK 1796398 · CHIEF EXECUTIVE OFFICER · last filed 2025-11-17

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$18.80M

Companies

4

Total Filings

16

Lifetime Open-Market Net

-$1.85M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LAVA Therapeutics NV (LVTX) Delisted Director $1.74 $0 2 2025-11-17
AGIO Director $29.46 $0 1 2025-07-10
SRRK CHIEF EXECUTIVE OFFICER 425,561 $44.18 $18.80M -$1.85M 7 2025-03-12
ACCELERON PHARMA INC (XLRN) Delisted EVP, Research and Development 0 $178.75 $0 $0 5 2021-11-22

Recent Filings · Page 2 of 2

16 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2022-09-22 SRRK Grant (A) $0 EDGAR
2021-11-22 ACCELERON PHARMA INC (XLRN) Delisted Mixed −21,233 $0 EDGAR
2021-02-02 ACCELERON PHARMA INC (XLRN) Delisted Grant (A) +5,409 $0 EDGAR
2021-01-06 ACCELERON PHARMA INC (XLRN) Delisted Tax (F) −1,735 -$215.7K EDGAR
2020-02-10 ACCELERON PHARMA INC (XLRN) Delisted Grant (A) $0 EDGAR
2020-01-03 ACCELERON PHARMA INC (XLRN) Delisted Grant (A) +17,107 $0 EDGAR
Showing 1116 of 16
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.